Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 35.70 and last traded at GBX 35.70, with a volume of 53907 shares trading hands. The stock had previously closed at GBX 39.50.
Faron Pharmaceuticals Oy Trading Down 9.6%
The company has a debt-to-equity ratio of 155.01, a current ratio of 2.40 and a quick ratio of 1.09. The company has a market capitalization of £72.43 million, a price-to-earnings ratio of -1.62 and a beta of 1.12. The business has a fifty day moving average price of GBX 40.97 and a 200 day moving average price of GBX 44.27.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
